Lavoltidine
Chemical compound
- none
- Development terminated
- [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
- 76956-02-0
- 55473
- 50093
- X16K5179V5
- DTXSID0020785
- Interactive image
- OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3
Lavoltidine (INN,[1] USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[3][4]
See also
- H2 receptor antagonist
- Sufotidine (analogous sequence in which a sulfonyl group replaces the hydroxyl group)
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). WHO Drug Information. 4 (3). World Health Organization: 7. 1990. Retrieved 12 January 2016.
- ^ "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
- ^ Washington N (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
- ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
- v
- t
- e
- Cimetidine
- Famotidine
- Lafutidine
- Lavoltidine (loxtidine)
- Nizatidine
- Ranitidine#‡
- Roxatidine
analogues ("-prost-")
("-prazole")
acid blockers ("-prazan")
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
- See also: Helicobacter pylori eradication protocols
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
